Tianjin TEDA Biomedical Engineering Company Limited (TEDA Biomedical) submitted its Monthly Return to Hong Kong Exchanges and Clearing on 1 April 2026, covering the month ended 31 March 2026. The filing shows no changes in either authorised or issued share capital during the period.

Authorised/Registered Capital • Ordinary H shares: 1.44 billion shares at RMB 0.10 par value. • Ordinary Domestic shares: 0.70 billion shares at RMB 0.10 par value. • Combined authorised/registered share capital: RMB 213.39 million (2.13 billion shares), unchanged from the previous month.

Issued Shares and Public Float • Issued H shares: 1.44 billion; issued Domestic shares: 0.70 billion. • No treasury shares were held. • The company confirmed compliance with the minimum 25 percent public-float requirement.

Corporate Instruments • No share options, warrants, convertibles, or other equity-related agreements were outstanding or exercised in March 2026.

The return was signed by Director Sun Li, affirming compliance with all applicable listing rules and regulatory requirements.